Search for: "Novartis Pharmaceuticals Corporation" Results 41 - 60 of 151
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Dec 2018, 2:23 pm by Lawrence B. Ebert
The outcome was reversal; Novartis wins:Novartis Pharmaceuticals Corporation and NovartisAG (collectively, Novartis) appeal the district court’sdecision to invalidate U.S. [read post]
6 Mar 2018, 2:10 pm by Tom Lamb
In closing this article, I will point out that in the US there still has not been any "Dear Doctor" letter sent nor any Tasigna drug label change made by Novartis Pharmaceuticals Corporation regarding atherosclerosis, despite the actions taken by its Canadian counterpart during April 2013. [read post]
16 Sep 2016, 4:07 am by John Collins
In the Actavis case, the applicants similarly argued that Orion’s agreement to supply finished product, or active pharmaceutical ingredients, to Novartis meant that the arrangement did not constitute an exclusive licence. [read post]
30 May 2011, 7:34 am by Steve McConnell
Novartis Pharmaceuticals Corp., No. 06-Civ-260 (BMC) (EDNY), and we’ve got some good news to report. [read post]
27 Feb 2018, 9:12 am by Tom Lamb
We point out that there was no similar "Dear Doctor" letter sent in the US by Novartis Pharmaceuticals Corporation in 2013, nor was any similar Tasigna drug label change made by Novartis in the US back then. [read post]
28 Apr 2013, 9:32 am by Ben Vernia
Even after entering into the corporate integrity agreement, Novartis’s compliance program failed to prevent kickbacks from being paid in conjunction with Novartis’s speaker programs. [read post]
20 Mar 2012, 7:55 am
In support, Novartis relied upon its earlier registered CTM ZIMBUS (2 356 954) in Class 5 for ‘pharmaceutical preparations’. [read post]
23 Sep 2010, 12:39 pm by FDABlog HPM
Karst –    On September 22, 2010, Novartis Pharmaceuticals Corporation (“Novartis”) filed a Complaint in the U.S. [read post]
30 Jun 2014, 4:23 am by Lawrence B. Ebert
Milliken & Company Northrop Grumman Corporation Novartis Patent Café.com, Inc. [read post]
17 Jun 2010, 6:47 am by Andrew Frisch
In its brief, the DOL argues that the district court in that case committed legal error when it concluded that the pharmaceutical sales representatives employed by Novartis Pharmaceutical Corporation (“NPC”) were exempt from the overtime requirements of the FLSA under the outsides sales and administrative exemptions. [read post]
11 Feb 2008, 9:20 am
February 2008 Australian Report Links Liver Failure And Hepatitis To Popular Novartis Drug (Posted by Tom Lamb at DrugInjuryWatch.com) A February 4, 2008 article, "Anti-fungal tablet linked to liver deaths", published by Australia's Herald Sun newspaper, brought to our attention the fact that Australian drug regulators have issued a warning about serious liver reactions after taking a popular prescription drug used to treat fungal infections, Lamisil (terbinafine),… [read post]
29 Oct 2019, 10:48 am by Jeffrey A. Newman
Braun Medical Inc.; Forest Laboratories, Inc.; GlaxoSmithKline LLC; Johnson & Johnson, Inc.; Janssen Pharmaceutical Products, LP; McNeil-PPC, Inc.; Ortho Biotech Products, LP; Ortho-McNeil Pharmaceutical, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmacia Corporation; and TAP Pharmaceutical Products, Inc. [read post]
1 Aug 2012, 7:04 pm
In this case, Novartis Pharmaceuticals Corporation sales representatives in 2006 claim that they were denied overtime pay which is a violation of the Fair Labor Standards Act. [read post]